139 related articles for article (PubMed ID: 9096940)
1. Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration.
Bottner RK; Hardigan KR
Cathet Cardiovasc Diagn; 1997 Apr; 40(4):380-2. PubMed ID: 9096940
[TBL] [Abstract][Full Text] [Related]
2. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.
Gibson CM; Cohen DJ; Cohen EA; Lui HK; Murphy SA; Marble SJ; Kitt M; Lorenz T; Tcheng JE
Am J Cardiol; 2001 Jun; 87(11):1293-5. PubMed ID: 11377359
[No Abstract] [Full Text] [Related]
3. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
4. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of coronary artery perforation during angioplasty using autologous vein graft-coated stent.
Chae JK; Park SW; Kim YH; Hong MK; Park SJ
Eur Heart J; 1997 Jun; 18(6):1030-2. PubMed ID: 9183598
[TBL] [Abstract][Full Text] [Related]
6. [Acute pericardial tamponade after percutaneous transluminal coronary angioplasty (PTCA). A rare life threatening complication].
Seggewiss H; Schmidt HK; Mellwig KP; Everlien M; Strick S; Fassbender D; Vogt J
Z Kardiol; 1993 Nov; 82(11):721-6. PubMed ID: 8291294
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
[TBL] [Abstract][Full Text] [Related]
9. Severe thrombocytopenia possibly related to readministration of eptifibatide.
Paradiso-Hardy FL; Madan M; Radhakrishnan S; Hurden S; Cohen EA
Catheter Cardiovasc Interv; 2001 Sep; 54(1):63-7. PubMed ID: 11553950
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
11. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
[TBL] [Abstract][Full Text] [Related]
12. A word of caution on optimizing stent deployment in calcified lesions: acute coronary rupture with cardiac tamponade.
Reimers B; von Birgelen C; van der Giessen WJ; Serruys PW
Am Heart J; 1996 Jan; 131(1):192-4. PubMed ID: 8554008
[No Abstract] [Full Text] [Related]
13. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
[TBL] [Abstract][Full Text] [Related]
15. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
[TBL] [Abstract][Full Text] [Related]
16. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
17. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting.
Salengro E; Mulvihill NT; Farah B
Catheter Cardiovasc Interv; 2003 Jan; 58(1):73-5. PubMed ID: 12508201
[TBL] [Abstract][Full Text] [Related]
18. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
19. Acute thrombocytopenia associated with eptifibatide therapy.
Khaykin Y; Paradiso-Hardy FL; Madan M
Can J Cardiol; 2003 Jun; 19(7):797-801. PubMed ID: 12813613
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Tardiff BE; Califf RM; Tcheng JE; Lincoff AM; Sigmon KN; Harrington RA; Mahaffey KW; Ohman EM; Teirstein PS; Blankenship JC; Kitt MM; Topol EJ
J Am Coll Cardiol; 1999 Jan; 33(1):88-96. PubMed ID: 9935014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
